You are subscribed to Oncology Drugs. This information has recently been updated, and is now available.

FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications

On July 9, 2026, the Food and Drug Administration approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S. LLC) for subcutaneous injection for multiple myeloma indications.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to Esdek@podam.pl using Granicus Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA